ReviewBMC cancer2017
ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Review in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Single-center experience using reflex-targeted next-generation sequencing at diagnosis of squamous cell lung carcinoma in daily practice.Virchows Archiv : an international journal of pathology · 2026Article
- High Efficacy of Chemoimmunotherapy in Advanced ALK-Rearranged Lung Squamous Cell Carcinoma: A Case Report.Cancer management and research · 2026Article
- Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases.Translational lung cancer research · 2025Article
- Efficacy analysis ofJournal of thoracic disease · 2024Article
- Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.BMC pulmonary medicine · 2023Article
- [Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation Treated with Ensartinib: A Case Report and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer.Journal of personalized medicine · 2023Review
- Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.Thoracic cancer · 2021Article
- Review
- Molecular biomarker testing for non-small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group.Journal of pathology and translational medicine · 2021Review
- ALK-rearranged squamous cell carcinoma of the lung.Thoracic cancer · 2021Article
- Review
- Case Report: A Case Report of a Histological Transformation ofPathology oncology research : POR · 2021Article
- Next-Generation Sequencing at High Sequencing Depth as a Tool to Study the Evolution of Metastasis Driven by Genetic Change Events of Lung Squamous Cell Carcinoma.Frontiers in oncology · 2020Article
- Lung cancer in never smokers-the East Asian experience.Translational lung cancer research · 2018Review
- Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.Oncotarget · 2018Article
- ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib.Case reports in oncological medicine · 2018Article
- Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.Therapeutic advances in respiratory diseaseReview
- Primary Unknown Squamous Cell Carcinoma with the Anaplastic Lymphoma Kinase Fusion Gene That Was Effectively Treated with Alectinib: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough anaplastic lymphoma kinase (ALK) fusion genes are generally identified in lung adenocarcinoma patients, they are relatively rare in patients with squamous cell carcinoma (SqCC). Metastatic ALK-rearranged lung adenocarcinoma patients treated with ALK inhibitors demonstrate higher response rates, improved progression-free survival, and reduced toxicity relative to those treated with conventional chemotherapy regimens. However, the efficacy of treatment with ALK inhibitors in patients with ALK-rearranged lung SqCC remains unknown. CASE PRESENTATION: We discuss a 52-year-old Japanese-Brazilian woman without a history of smoking who was referred to our hospital for evaluation of severe left back pain and a left hilar mass observed on a chest radiograph. The patient was eventually diagnosed on the basis of computed tomography, pathological, and immunohistochemical findings as having Stage IV lung SqCC. First-line treatment with palliative radiotherapy and systemic chemotherapy with cisplatin plus vinorelbine was administered, but was not effective. ALK testing was subsequently performed, revealing positive ALK expression and gene rearrangement. Alectinib therapy was then initiated, which resulted in a gradual, but substantial reduction in tumor size.
conclusionsTo the best of our knowledge, this is the first case report to discuss the successful management of ALK-rearranged lung SqCC with alectinib. We propose that molecular testing for driver mutations should be considered in young patients with a light or no smoking history, even if the histological findings correspond with SqCC, and alectinib therapy represents a reasonable option in cases of ALK-rearranged lung SqCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.